![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 13, 2019 11:08:57 AM
March 12, 2019
Tags: NewsPoints Osiris Smith & Nephew United States Corporate Affairs Mergers &
Acquisitions
A group of Osiris Therapeutics Inc. shareholders are attempting
to block the $660.5 million purchase of the company by Smith & Nephew plc.
The shareholders allege that the purchase price of $19 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. In addition, shareholders allege that Osiris senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.
Osiris Therapeutics did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Osiris Therapeutics for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or contact@tripplevy.com
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM